Needham & Company LLC restated their buy rating on shares of Annexon (NASDAQ:ANNX - Free Report) in a research report released on Tuesday,Benzinga reports. The brokerage currently has a $16.00 price objective on the stock.
Other equities research analysts also recently issued research reports about the company. Cantor Fitzgerald reiterated an "overweight" rating on shares of Annexon in a research report on Friday, November 15th. HC Wainwright reaffirmed a "buy" rating and issued a $30.00 price target on shares of Annexon in a report on Tuesday, December 17th. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, Annexon presently has an average rating of "Buy" and a consensus target price of $15.80.
Read Our Latest Report on ANNX
Annexon Price Performance
Shares of ANNX traded up $0.08 during midday trading on Tuesday, hitting $2.76. 719,370 shares of the company traded hands, compared to its average volume of 1,810,568. Annexon has a one year low of $2.30 and a one year high of $8.40. The firm has a market cap of $294.20 million, a P/E ratio of -2.63 and a beta of 1.14. The stock has a 50-day moving average of $3.80 and a 200-day moving average of $5.36.
Annexon (NASDAQ:ANNX - Get Free Report) last posted its earnings results on Monday, March 3rd. The company reported ($0.33) earnings per share for the quarter, missing analysts' consensus estimates of ($0.28) by ($0.05). Sell-side analysts forecast that Annexon will post -0.96 EPS for the current fiscal year.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently added to or reduced their stakes in ANNX. BNP Paribas Financial Markets bought a new stake in Annexon during the fourth quarter worth about $59,000. CANADA LIFE ASSURANCE Co purchased a new position in shares of Annexon during the 4th quarter valued at about $77,000. E Fund Management Co. Ltd. raised its holdings in shares of Annexon by 36.0% during the 4th quarter. E Fund Management Co. Ltd. now owns 15,447 shares of the company's stock valued at $79,000 after buying an additional 4,086 shares in the last quarter. Forefront Analytics LLC lifted its position in Annexon by 56.8% in the 4th quarter. Forefront Analytics LLC now owns 16,433 shares of the company's stock worth $84,000 after buying an additional 5,950 shares during the last quarter. Finally, KLP Kapitalforvaltning AS purchased a new stake in Annexon in the fourth quarter worth approximately $98,000.
About Annexon
(
Get Free Report)
Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.
Featured Articles
Before you consider Annexon, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Annexon wasn't on the list.
While Annexon currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
